Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong.
Evid Based Complement Alternat Med. 2013;2013:327245. doi: 10.1155/2013/327245. Epub 2013 May 8.
Objective. The aim of this study is to investigate the effectiveness and safety of a Chinese herbal formula Zi Shen Qing (ZSQ) in the treatment of systematic lupus erythematosus (SLE) in Chinese patients. Methods. A randomized controlled trial was conducted over 12 weeks in 84 Chinese patients who reported total scores of SLE Disease Activity Index-2000 (SLEDAI-2000) was from 5 to 14. The primary outcome was the changes of the SLEDAI-2000. The secondary outcomes included score changes of Chinese Medicine Syndromes (CMS), the changes of steroid dosage, the incidence of disease flare-up and biologic markers. Results. ZSQ significantly reduced SLEDAI-2000, the total scores of CMS in the treatment group compared with the controlled group (P < 0.05). Superiority of ZSQ over controlled group was also observed with greater improvement in the withdrawal dosage of corticosteroids and the incidence of disease flare-up (P < 0.05). There were no serious adverse events, and safety indices of whole blood counts, renal and liver functions were normal, both before and after the treatment. Conclusion. ZSQ is safe and effective for decreasing SLE disease activity and withdrawal dosage of corticosteroids in the mild to moderate SLE patients with "Deficiency of Qi and Yin" Pattern.
目的。本研究旨在探讨中药复方自圣清(ZSQ)治疗中国系统性红斑狼疮(SLE)患者的疗效和安全性。
方法。在 84 名总 SLE 疾病活动指数-2000(SLEDAI-2000)评分在 5 至 14 分的中国患者中进行了为期 12 周的随机对照试验。主要结局是 SLEDAI-2000 的变化。次要结局包括中医证候(CMS)评分的变化、类固醇剂量的变化、疾病发作的发生率和生物标志物。
结果。与对照组相比,ZSQ 显著降低了 SLEDAI-2000 和治疗组的 CMS 总评分(P < 0.05)。ZSQ 还观察到更好的皮质类固醇撤药和疾病发作的改善(P < 0.05)。没有严重的不良事件,全血细胞计数、肾功能和肝功能的安全指标在治疗前后均正常。
结论。ZSQ 安全有效,可降低轻度至中度“气阴两虚”型 SLE 患者的 SLE 疾病活动度和皮质类固醇撤药剂量。